Stay updated with breaking news from Core Opinc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(RTTNews) - Novartis (NVS) said the U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) 'combination pate...
Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal to the U.S. Court of Appeals for the Federal Circuit to reverse the District Court’s rulingNo generic Entresto product has received FDA approval as of todayPending a final appeal decision and other ongoing litigation involving multiple patents, any launch once generics receive FDA approval would be ‘at risk
Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto ‘combination patent’ to be invalid Novartis will appeal to the U.S....
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating